<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>529-TRICLABENDAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TRICLABENDAZOLE" rxcui="38608">
<ATC code="P02BX04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DIHYDROERGOTAMINE" rxcui="3418">
<ATC code="N02CA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>Wait 24 hours between stopping the triclabendazole and the dose of the medication derived from ergot of rye, and the reverse.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>529-TRICLABENDAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TRICLABENDAZOLE" rxcui="38608">
<ATC code="P02BX04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ERGOTAMINE" rxcui="4025">
<ATC code="N02CA02" />
<ATC code="N02CA51" />
<ATC code="N02CA52" />
<ATC code="N02CA72" />
</DRUG>
</DRUG2>
<DESCRIPTION>Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>Wait 24 hours between stopping the thiclabendazole and the ergotamine, and the reverse.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>529-TRICLABENDAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TRICLABENDAZOLE" rxcui="38608">
<ATC code="P02BX04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PIMOZIDE" rxcui="8331">
<ATC code="N05AG02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes (inhibition of the hepatic metabolism of the torsade inducing medication)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>Wait 24 hours between stopping the triclabendazole and the dose of the torsade inducing medication, and the reverse. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>529-TRICLABENDAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TRICLABENDAZOLE" rxcui="38608">
<ATC code="P02BX04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="QUINIDINE" rxcui="9068">
<ATC code="C01BA01" />
<ATC code="C01BA51" />
<ATC code="C01BA71" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes (inhibition of the hepatic metabolism of the torsade inducing medication)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>Wait 24 hours between stopping the triclabendazole and the dose of the torsade inducing medication, and the reverse.</COMMENT>
</INTERACTION>
</INTERACTIONS>
